A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression in the US. The FDA first approved the Johnson & Johnson drug ...
We specialize in treatment resistant DEPRESSION ... Esketamine, branded as Spravato, also covered by insurance, is a nasal spray that works on different neurotransmitter systems in the brain ...
March 6, 2025 – The FDA has approved a new nose spray that can quickly ... Parents and caregivers should inform their child’s health care provider about any nasal issues, heart, kidney ...